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Background: Lung radiation injury is a critical complication of radiotherapy (RT) for thoracic esophageal carcinoma
(EC). Therefore, the goal of this study was to investigate the feasibility and dosimetric effects of reducing the lung
tissue irradiation dose during RT for thoracic EC by applying volumetric modulated arc radiotherapy (VMAT)
combined with active breathing control (ABC) for moderate deep inspiration breath-hold (mDIBH).
Methods: Fifteen patients with thoracic EC were randomly selected to undergo two series of computed tomography
(CT) simulation scans with ABC used to achieve mDIBH (representing 80% of peak DIBH value) versus free breathing (FB).
Gross tumor volumes were contoured on different CT images, and planning target volumes (PTVs) were obtained using
different margins. For PTV-FB, intensity-modulated radiotherapy (IMRT) was designed with seven fields, and VMAT included
two whole arcs. For PTV-DIBH, VMAT with three 135° arcs was applied, and the corresponding plans were named:
IMRT-FB, VMAT-FB, and VMAT-DIBH, respectively. Dosimetric differences between the different plans were compared.
Results: The heart volumes decreased by 19.85%, while total lung volume increased by 52.54% in mDIBH,
compared to FB (p < 0.05). The mean conformality index values and homogeneity index values for VMAT-DIBH
(0.86, 1.07) were slightly worse than those for IMRT-FB (0.90, 1.05) and VMAT-FB (0.90, 1.06) (p > 0.05). Furthermore,
compared to IMRT-FB and VMAT-FB, VMAT-DIBH reduced the mean total lung dose by 18.64% and 17.84%,
respectively (p < 0.05); moreover, the V5, V10, V20, and V30 values for IMRT-FB and VMAT-FB were reduced by 10.84%
and 10.65% (p > 0.05), 12.5% and 20% (p < 0.05), 30.77% and 33.33% (p < 0.05), and 50.33% and 49.15% (p < 0.05),
respectively. However, the heart dose-volume indices were similar between VMAT-DIBH and VMAT-FB which were
lower than IMRT-FB without being statistically significant (p > 0.05). The monitor units and treatment time of
VMAT-DIBH were also the lowest (p < 0.05).
Conclusions: VMAT combined with ABC to achieve mDIBH is a feasible approach for RT of thoracic EC.
Furthermore, this method has the potential to effectively reduce lung dose in a shorter treatment time and with
better targeting accuracy.
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Esophageal carcinoma (EC) is one of the most common
malignant tumor types worldwide, and its incidence con-
tinues to rise [1]. Currently, complete surgical resection
is the standard treatment for patients with EC who are
medically fit [2]. However, chemo-radiotherapy has also* Correspondence: yongyinsd@163.com
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reproduction in any medium, provided the orachieved promising clinical outcomes for patients with
advanced local EC, including squamous cell cancer and
adenocarcinoma, as well as for those who are not fit for
surgery [2-4]. Radiation therapy (RT) also continues to be
a critical component for multimodality systemic treatment
of EC [5,6]. However, treatment-related pneumonitis is
an acute and toxic side effect that can occur with RT for
thoracic EC [7]. Advances have been made in RT technology
that can be applied to EC, including the progressiontd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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radiotherapy (3D-CRT), intensity modulated radiotherapy
(IMRT), intensity proton beam radiotherapy (IMPT), volu-
metric modulated radiotherapy (VMAT), and helical tomo-
therapy (HT) [5,8-13]. In particular, IMRT, VMAT, and
HT have achieved a more conformal and homogeneous
dose distribution with the application of beam intensity
modulated technology and a multileaf collimator (MLC)
system compared with 3D-CRT. VMAT also represents
an extension of IMRT which facilitates synchronized
variations in gantry speed, dose rate, and the shape of
the MLC and jaws [14,15]. Consequently, VMAT can
achieve similar, if not better, dose distribution compared
with IMRT with shorter treatment times and fewer
monitor units (MUs) [15-19]. The application of VMAT
to EC RT has obtained similar results, although a more
extensive low dose region is involved which can affect
normal tissue [9-13]. However, given the shorter duration
of the treatment associated with VMAT and the other
technologies available, the damage to normal tissue can be
minimized [19].
During RT for thoracic EC, displacement and deform-
ation induced by breath motion are critical factors which
affect treatment accuracy and precision. For example, in a
report by Yanashita et al. [20], the average displacements in
the cranial-caudal (CC) for the upper, middle, and lower
thoracic esophagus were 3.2 mm (range, 0.7–5.5 mm),
6.4 mm (range, 1.5–14.5 mm), and 10.3 mm (range,
4.0–16.3 mm), respectively. In comparison, the displace-
ment of the left-right (L-R) and anterior-posterior (AP)
regions were smaller. However, application of active
breathing control (ABC) has been observed to reduce
the motion induced by respiration [21,22]. In addition,
lung volume can be effectively increased with DIBH,
and this has the benefit of sparing lung tissue during
RT. Therefore, the feasibility and dosimetric features
of VMAT combined with ABC for mDIBH for RT of
thoracic EC were investigated.
Methods
Patients
A total of 15 patients (5 females, 10 males) ranging in age
from 42–65 y (median, 53.5 y) had pathologically proven
thoracic squamous cell EC and were randomly selected
from the patients treated at our hospital between March
2010 and December 2011. Cardiopulmonary function for
each patient was carefully and objectively examined prior
to enrollment in the study to ensure that the patients
could coordinate ABC. All of the enrolled patients had
good cardiopulmonary function with Karnofsky perform-
ance scores (KPS) ranging from 80–90. None of the pa-
tients had communication barriers with the administrators
of this study, and the breath holding time in mDIBH with
ABC for all patients reached 30 s. This study was approvedby the Research Ethics Board of the Shandong Cancer
Hospital, and all patients agreed to the conditions of this
trial. Completed informed consent forms were obtained
from each patient.Computed tomography (CT) simulation
For each patient, two serious CT scans were performed
using a Philips Brilliance CT Big Bore (Phillips Medical
Systems, 96 Highland Heights, OH, USA). For mDIBH,
CT scans were performed using the Elekta ABC system
(Synergy 102™, Elekta, Crawley, UK), with the trigger
threshold set at 80% of the peak value of DIBH. In
addition, the latter scans were acquired after scanning
with FB. Furthermore, breath training was performed at
least twice by each patient prior to scanning. Patients were
also immobilized using a body vacuum pillow and their
arms were extended above their head.
All CT scans were acquired in spiral model (pitch = 0.938,
table speed = 30 mm/s, reconstruction slice thickness =
3.0 mm) and the region scanned extended from the crico-
thyroid membrane to the lower edge of the liver. All CT
images were transmitted to aVarian Eclipse treatment plan-
ning system (TPS) (version 8.6.15, Varian Medical Systems,
Palo Alto, CA, USA) to determine target volumes, organs
at risk (OARs) contouring, and the design of RT plans.Gross tumor volume (GTV) and planning target volume
(PTV) acquisition
An experienced radiation oncologist contoured the GTV
delineated on each CT image, and this region included
the tumor and pathologically involved lymph nodes. The
clinical target volume (CTV) included the GTV as well
as an additional 3–5 cm in the cranio-caudal direction
along the esophagus in order to include the possibility
of microscopic spread. The PTV for FB plans (PTV-FB)
included the addition of a 1.5 cm margin (for internal
motion and setup error) which was applied in all three
dimensions to the CTV [21]. Furthermore, the PTV for
the mDIBH plans (PTV-DIBH) included an additional
1 cm margin to account for setup variation and ABC
reproducibility (i.e., uncertainty of organ position with
ABC), in as much as the tumor was immobilized during
breath-hold [21-23]. Healthy lung tissue was also included
in the total lung volume, while GTV was excluded.Radiotherapy plans
Both IMRT and VMAT plans were designed for PTV-FB,
while VMAT was designed only for PTV-DIBH. These plans
were administered using a VARIAN Trilogy linear acceler-
ator (Varian Medical Systems, Palo Alto, CA, USA), and
were named IMRT-FB, VMAT-FB, and VMAT-DIBH, respect-
ively. The details of each plan are as follows:
Table 1 Target volumes and OAR volumes for FB and
DIBH CT techniques (cm3)
Volume FB (cm3) DIBH (cm3) T p
GTV 52.58 ± 19.72 46.40 ± 20.78 0.610 0.552
PTV 396.11 ± 72.43 270.91 ± 87.02 2.259 0.040
Total lung 4039.40 ± 79.86 6161.60 ±80.85 −5.282 0.000
Heart 621.08 ± 66.84 497.80 ± 86.58 3.188 0.007
GTV Gross tumor volume, PTV Planning target volume.
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A step-and-shoot mode was applied for seven coplanar
fields with gantry angles set at 0°, 51°, 102°, 153°, 204°,
255°, and 306°. The intensity level was 20 and the dose
rate was 400 MU/min.
VMAT-FB plan
Dual coplanar whole arcs were employed. One arc was
performed in a clockwise direction from 181° to 179° with
a 45° collimator angle. Conversely, the second arc was
performed in a counterclockwise direction from 179°
to 181° with a 315° collimator angle. The two arcs were
optimized simultaneously and were delivered in opposite
rotation with a maximum dose rate of 600 MU/min.
VMAT-DIBH plan
Three partial 135° arcs were employed according to the
breath holding time with mDIBH. The gantry angles of
the three arcs were set to start counterclockwise from
179° to 44°, from 67° to 292°, and from 316° to 181°. More-
over, two arcs were allowed to overlap in the mediastinal
region. The collimator angle was set to 45° for the first and
third arcs, and at 315° for the second arc. The maximum
dose rate was 600 MU/min.
All plans were optimized using a six megavolts (MV)
X-ray, and the objective dose-volume parameters were
identical at the beginning of optimization for the different
plans, and the parameters were adjusted following optimi-
zation until the results approached an ideal setting.
A VARIAN Triliogy linear accelerator equipped with a
Millenni-um-120 MLC (120 leaves with a resolution at
isocenter of 5 mm for the inner 20 cm and 10 mm for
the outer 2 × 10 cm) was used. The gantry speed was set
at 4.8°/s. For all plans, the prescription dose for the PTV
was 2 Gy/fraction × 30 fractions [24]. Dose constraints
for complications included minimizing doses for health
lung (named total lung), heart, and spinal cord, while
maintaining optimal target coverage and dose uniformity
to the target volumes. In addition, the mean PTV dose
was normalized to 100% of the iso-dose line. All dose
distributions were computed using an analytical anisotropic
algorithm available in the Eclipse planning system, and
the dose grid resolution was 2 mm.
Plan evaluations
The irradiation doses needed to target 1% and 99% of
the PTVs (D1% and D99%, respectively) were designated as
the maximum and minimum doses, respectively.
Homogeneity index (HI) values were calculated based
on the radiation dose ratio of 5% and 95% of the PTVs
(D5% and D95%, respectively), e.g., HI = D5%/D95%.
Conformality index (CI) values were calculated according
to the Van’t Riet definition: CI = (TVRI/TV) × (TVRI/VRI),
where TVRI is the target volume covered by the referenceisodose, TV is the target volume, and VRI is the volume of
the reference isodose [25]. CI and HI values are ideal when
they approach a value of 1.
Comparisons were made between the different treatment
plans in regard to mean irradiation dose, the percentage
of the x Gy radiation dose applied to a volume of healthy
tissue (VxGy), including for the lung (e.g., V5, V10, V20, V30,
and V40) and heart (e.g., V20, V30, and V40), the maximum
radiation dose applied to the spinal cord, MUs, and treat-
ment time.Statistical analysis
All results are reported as the average ± standard deviation
( X  S) and SPSS 16.0 software (IBM, Chicago, IL, USA)
was used for all statistical analyses. A paired t-test was
used to compare total lung and heart volumes, GTV,
and PTV for each breath status. One-way analysis of
variance (ANOVA) was used to compare indices among
different plans, and the difference between two plans
was compared using Bonferroni multiple comparison
test. Differences were considered statistically significant
when the p-value was less than 0.05.Results
Comparison of GTV, PTV, total lung and heart volumes
As shown in Table 1, the mean GTV volume determined
with FB was 11.75%, and this was greater than that deter-
mined with mDIBH. However, this difference was not
statistically significant (p > 0.05). In contrast, mean PTV
and heart volume decreased (31.61% and 19.85%, respect-
ively), while mean total lung volume increased (52.54%),
with mDIBH. Furthermore, each of those differences were
statistically significant (p < 0.05).Dose distribution of PTV
The D1% and D99% were similar among the IMRT-FB,
VMAT-FB and VMAT-DIBH plans (p > 0.05). The CI and
HI values for VMAT-DIBH were slightly worse than
those for IMRT-FB and VMAT-FB, and these differences
were not statistically significant (p > 0.05). Meanwhile,
CI and HI values were similar for the IMRT-FB and
VMAT-FB plans (p > 0.05).
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The VMAT-DIBH plan significantly reduced the mean dose
and the V5 to V40 values for total lung compared with the
IMRT-FB and VMAT-FB plans (except for V5, as shown in
Table 2) (p < 0.05). The V10 of VMAT-FB was also higher
than that of the IMRT-FB plan, yet the difference was
not significant (p > 0.05). The mean dose, V5, V20, V30,
and V40 were also similar for the IMRT-FB and VMAT-FB
plans (p > 0.05).
For the heart, the V20, V30, and V40 values were similar
between the VMAT-DIBH and VMAT-FB plans (p > 0.05),
and these values were lower than those of the IMRT-FB
plan. The mean irradiation dose for the heart was also
similar between the IMRT-FB and VMAT-FB plans, and
these doses were higher than that for the VMAT-DIBH
plan.
There were no significant differences in the Dmax values
for the spinal cord among the plans (p > 0.05).
MUs and delivery time
MUs for the IMRT-FB plan (798.38 ± 112.99) were sig-
nificantly greater than those for the VMAT-FB (508.25 ±
64.95) and VMAT-DIBH (506.88 ± 78.87) plans (p < 0.05).Table 2 Dose-volume indices of the PTV and OARs
Variable IMRT-FB VMAT-FB VMAT-DIBH F p
PTV
D1% (Gy) 65.67 ± 0.41 65.74 ± 0.35 66.10 ± 0.44 2.599 0.098
D99% (Gy) 58.82 ± 0.52 58.76 ± 0.51 58.35 ± 0.41 2.156 0.141
CI 0.90 ± 0.03 0.90 ± 0.03 0.86 ± 0.04 2.864 0.079
HI 1.05 ± 0.02 1.06 ± 0.02 1.07 ± 0.03 2.485 0.107
Total lung
V5 (%) 83 ± 9 83 ± 9 74 ± 10 2.274 0.128
V10 (%) 64 ± 9 70 ± 10 56 ± 10 4.808 0.019
V20(%) 26. ± 5 24 ± 6 18 ± 4 5.518 0.012
V30 (%) 8 ± 4 8 ± 3 4 ± 2 4.062 0.032
V40 (%) 4 ± 2 4 ± 1 2 ± 0 3.790 0.039
Dmean (Gy) 15.45 ± 2.24 15.30 ± 2.19 12.57 ± 1.78 4.884 0.018
Heart
V20 (%) 71 ± 2.46 61 ± 2.77 61 ± 2.73 0.336 0.719
V30 (%) 38 ± 2.37 36 ± 2.35 35 ± 2.20 0.032 0.968
V40 (%) 22 ± 1.42 20 ± 1.40 19 ± 1.25 0.097 0.908
Dmean 28.83 ± 8.60 28.82 ± 8.71 27.32 ± 8.53 0.080 0.923
Spinal cord
Dmax(Gy) 43.54 ± 2.62 44.83 ± 2.19 41.25 ± 4.40 2.542 0.103
Monitor
units
798.38 ± 11.20 508.25 ± 6.49 506.88 ± 7.88 29.156 0.000
Treatment
time (s)
367.64 ± 3.39 170 ± 0 124 ± 0 349.997 0.000
CI Conformality index, HI Homogeneity index.The estimated treatment time (from first filed beam-on
to the last filed beam-off ) for VMAT-DIBH (124 ± 0 s)
was also shorter than that for VMAT-FB (170 ± 0 s), and
was also significantly shorter than the measured treatment
time for IMRT-FB (367.64 ± 33.90 s) (p < 0.05).
Discussion
Previously, VMAT has been shown to achieve better dose
delivery with a shorter treatment time and fewer MUs
[10-20]. However, VMAT has also been associated with a
larger low dose region that affects OARs in some cases
[10-17]. Correspondingly, differences in lung V10 between
the VMAT-FB and IMRT-FB plans in the present study
were observed.
Treatment-related pneumonitis represents critical radi-
ation toxicity during RT for thoracic EC, and dose-volume
indices are commonly used to predict this side effect
[26-28]. While V20, V30, and the mean lung dose have been
considered classic predictors of treatment-related pneu-
monitis, the predictive value of V5, V10, and V13 have also
been considered [29-31]. Therefore, the approach which
reduces lung dose for all dose-volume indices, provides
sufficient PTV coverage, and achieves perfect dose distri-
bution, is preferred [32]. Accordingly, VMAT represents a
preferred method based on its shorter treatment time,
fewer MUs, and better dose delivery. Furthermore, in asso-
ciation with ABC, VMAT may potentially spare a greater
region of normal tissue from damage [33].
The displacement and deformation of thoracic EC caused
by breath motion can significantly affect the precision of
RT. In addition, the randomness of breath phase at the
scanning moment with FB can potentially introduce more
uncertainty. This is usually compensated for with larger
margins. However, if the margins are extended too far, this
can increase the probability that radiation injury will
occur. Accordingly, the ability to reduce breath motion
is important, especially for patients with distal EC. The
application of ABC with mDIBH was found to further
reduce lung radiation dose by increasing the absolute
lung volume.
At the beginning of this study, IMRT and ABC were
combined for RT of EC. However, the feasibility of this
approach was limited by the longer time needed for each
field and fraction of IMRT. Each IMRT plan has seven
fields, and sometimes one field may be divided into more
than one subfield, potentially leading to 14 or more
subfields. In addition, patients need to rest for at least six
intervals, and this may compromise the reproducibility
of the breath hold motion due to muscle fatigue. Second,
if one field or subfield is not completed within the breath-
holding time of the patient, it is difficult to ensure that the
relative position of the MLC and PTV will be identical to
the moment of beam off. Regarding the VMAT plans,
completing a whole arc using segments was not feasible,
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tainty [33]. Therefore, duration of treatment for each field
and fraction, as well as the risk of secondary tumors for
patients who survive for an extended period of time, are
important factors to consider. In addition, for the whole
arc(s) VMAT plans, a larger low dose region affecting
OARs was observed, although good dose delivery was
achieved in a shorter period of time and with fewer MUs
using these plans.
It was observed that the VMAT-DIBH plans with three
135° arcs were associated with lower CI values than the
IMRT-FB and VMAT-FB plans, although the differences were
not significant. A possible reason for this phenomenon is
that VMAT-DIBH involves fewer control points than the
other plans. Thus, another arc < 135° may be needed to
raise CI values [34]. For the VMAT-FB plan, it contained
3–4 arcs (including 2–3 rest times for the patient), which
is reasonable to ensure the reproducibility and stability of
the breath hold motion based on our experience with
RT and ABC applied to breast cancer, lung cancer, and
hepatocellular carcinoma.
ABC has been shown to be an effective approach for
improving the precise application of RT for thoracic and
abdominal cancer. Specifically:
(1)ABC facilitates the positioning of the target volume
of a tumor by limiting the motion of the target
volume induced by respiration. Consequently,
margins between the CTV and the PTV were able to
be reduced by effectively restricting respiratory
motion. Moreover, OARs were able to be spared by
ensuring accurate positioning of the tumor [33].
(2)DIBH can increase lung volume, thereby sparing
normal lung tissue during treatment. Moreover, the
use of ABC to improve DIBH has previously been
applied to RT for breast cancers, lung cancers, and
lymphomas, with positive results reported [35].
(3)The use of ABC to achieve varying degrees of breath
status, including DIBH, deep expiratory hold
(DEBH), or mDIBH, potentially changes the spatial
relationship between tumor and OARs, and this may
subsequently affect the dose-volume of OARs.
In this study, the lower radiation dose for lung tissue
can be attributed to the reduction in PTV margins and the
increase in lung volume with DIBH. Total lung volume and
dose-volume parameters for the lung are two important
factors [36]. Displacement of the ECs in different directions
was not able to be clearly determined in the present study,
although it is possible to measure these parameters using
4D-CT. In simulations, respiratory phase randomness was
associated with too much uncertainty regarding GTVFB,
and this uncertainty was effectively reduced with the use of
DIBH. Furthermore, the 5 mm reduction in tumor marginswas found to be moderate and reasonable in the present
study [20,21], and dosimetric benefit was maintained in
relation to lung volume if the same margins were applied
for PTV-FB and PTV-DIBH. Heart volume with mDIBH
was also significantly smaller than with FB, while the
dose-volume indices for VMAT-DIBH were lower than
those of IMRT-FB and VMAT-FB. These results were very
promising, although the dose-volume indices did not dif-
fer significantly. This may be due to the spatial limitation
of heart beats during DIBH, reductions in tumor margins,
and the increased distance for PTV.
Overall, VMAT combined with ABC in the present
study achieved good, accurate dose distribution, involved
a shorter treatment time, and reduced low dose exposure
of OARs. The total treatment time was approximately
115 s, which includes the rest time for the patient and the
gantry rotation time for beam preparation. Moreover, this
period of time is shorter than that needed to complete
double whole arc VMAT. CI values can also increase with
low speed gantry rotation, and this speed should be as fast
as possible, as soon as possible, in order to reduce the
uncertainty of RT, especially when applying ABC [37].
The prescription dose used in this study was 60 Gy/30 F,
and was selected based on survival rates versus escalating
dose. In addition, another radiation therapy oncology
group (RTOG) had previously demonstrated that a dose
of 50.4 Gy was associated with an acceptable clinical
outcome [38,39]. In particular, lung irradiation dose was
found to be the major limiting factor for increasing the
PTV dose. However, using VMAT with ABC for mDIBH,
the prescription dose could be higher. Although the dosi-
metric benefits were evaluated by comparing treatment
strategies, the reproducibility of these results need to be
confirmed, particularly regarding the clinical benefit of
the breath hold motion. However, clinical outcome may
not be obtained in a short period of time. Therefore,
incorporation of image-guided RT could further improve
the precision of the currently proposed method without
significantly increasing treatment time. In addition, patients
treated in the present study will continue to be monitored
in order to verify the current results and to improve the
design of future studies.Conclusions
VMATcombined with ABC for mDIBH achieved a similar
dose distribution for tumor targets and spared OARs
to a greater extent than IMRT and double whole arc
VMAT with FB. Therefore, VMAT combined with ABC
for mDIBH is recommended for thoracic EC patients
with good cardiopulmonary function.Competing interests
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